H. Pylori Infection Clinical Trial
Helicobacter pylori infection is associated with several gastric diseases, including
gastritis, peptic and duodenal ulcers, gastric carcinoma and MALToma. In 1994, the WHO
classified the organism as a type 1 carcinogen. In order to eradicate H. pylori, at least
two antibiotics and a proton pump inhibitor are used as a standard therapy regimen. Emerging
antibiotic resistance to metronidazole or clarithromycin, however, has made successful
treatment of infection progressively more difficult, with the success rate of standard
triple therapy now at 70%, well below the 80% required for treatment of infectious diseases.
Therefore, new treatment regimen is required for successful H. pylori eradication.
On the other hands, many in vitro studies revealed that bacterial carbonic anhydrase in H.
pylori has an important role for surviving of H. pylori in the stomach. It was demonstrated
that mutation of carbonic anhydrase affected survival of H. pylori. The investigators
therefore expected that administration of carbonic anhydrase inhibitor (acetazolamide) with
standard H. pylori eradication regimen would increase the eradication rate. Here, the
investigators aim to evaluate the efficacy of standard triple regimen plus acetazolamide for
H. pylori eradication.
n/a
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Active, not recruiting |
NCT06045494 -
The Efficacy of Treatment for Helicobacter Pylori Infection in Preschooler by Yoghurt With LG21
|
N/A | |
| Not yet recruiting |
NCT01449500 -
Supplementation With L. Reuteri in H. Pylori Infected Adults
|
N/A | |
| Completed |
NCT01234389 -
Immediate Detection of Helicobacter Infection With a New Electrochemical System.
|
N/A | |
| Not yet recruiting |
NCT05387005 -
Screening Strategy for Gastric Cancer Prevention
|
N/A | |
| Not yet recruiting |
NCT02761005 -
Eradication of H. Pylori Therapy Individualized by the Mutation of 23S rRNA of H. Pylori
|
Phase 2 | |
| Recruiting |
NCT03142620 -
Effect of Vitamin D on Drug Resistant Helicobacter Pylori (HP) Eradication Study
|
Phase 3 | |
| Recruiting |
NCT01335334 -
H. Pylori Eradication Using Pyklear in Adults in El Paso, Texas: a Pilot Study
|
Phase 4 | |
| Recruiting |
NCT05544396 -
Study on the Probiotics Regulating miRNA in H. Pylori-induced Wnt/β-catenin Gastric Carcinogenesis.
|
N/A | |
| Recruiting |
NCT04713670 -
Comparison of Vonoprazan-based Versus Lansoprazole-based Triple Therapy, High Dose Dual Therapy, Bismuth and Non-bismuth Quadruple Therapy in the First-line Treatment of Helicobacter Pylori Infection
|
Phase 4 | |
| Recruiting |
NCT06045832 -
Oral Helicobacter Pylori Eradication
|
N/A | |
| Completed |
NCT05453994 -
Bismuth for PCAB-based H. Pylori Eradication
|
||
| Recruiting |
NCT02328131 -
European Registry on the Management of Helicobacter Pylori Infection
|
||
| Completed |
NCT00197457 -
Pepsinogens as the Early Marker of H. Pylori Eradication
|
Phase 2 | |
| Not yet recruiting |
NCT06412640 -
Optimization of Keverprazan-amoxicilli Dual Therapy for Helicobacter Pylori
|
Phase 4 | |
| Completed |
NCT04036838 -
ARJ C13 Urea Breath Test System
|
Phase 2 | |
| Completed |
NCT06050824 -
A Comparative Study Between Concomitant Versus Load Therapy in Eradication of Helicobacter Pylori Infection
|
Phase 4 | |
| Completed |
NCT02767479 -
Comparison of Rabeprazole and Esomperazole for the Eradication of H. Pylori
|
Phase 3 | |
| Completed |
NCT01505127 -
Efficacy of TAK-438, Amoxicillin and Clarithromycin in the First Line Eradication of H. Pylori
|
Phase 3 | |
| Recruiting |
NCT05176821 -
Eradication Efficacy and Safety of Two Rescue Treatments for Helicobacter Pylori Infection
|
N/A | |
| Completed |
NCT05002595 -
H. Pylori Treatment Between Modified Quadruple Regimen and Tailored Therapy
|